



Muhammad Darwin Prenggono <muh.darwin.prenggono@gmail.com>

ONCOL - Submission ORCID

1 message

Paola Granata <paola.granata@pagepress.org>

Fri, Aug 27, 2021 at 3:53 PM

To: Muhammad Darwin Prenggono <muh.darwin.prenggono@gmail.com>

Dear Muhammad Darwin Prenggono,

You have been listed as an author on a manuscript submission to Oncology Reviews.
To confirm your authorship, please add your ORCID id to this submission by visiting the link provided below.


 [Register or connect your ORCID iD](#)

[More information about ORCID at Oncology Reviews](#)


If you have any questions, please contact me.

Paola Granata

[Oncology Reviews](#)



Gambar. Tangkapan layar bukti pengiriman naskah publikasi berjudul “*The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review*” pada sistem pengiriman jurnal *Oncology Reviews*



Gambar. Tangkapan layar bukti hasil review pakar (*peer-review*) untuk melakukan revisi naskah publikasi berjudul "*The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review*" pada sistem pengiriman jurnal *Oncology Reviews*

ONCOL - Oncology Reviews [paper #547] - Editor Decision - Revisions Required

Dear Muhammad Darwin Prenggono, Alfi Yasmina, Misna Ariyah, Tenri Ashari Wanahari, Nuvita Hasrianti,

Your paper entitled "The Effect of Imatinib and Nilotinib on Blood Calcium and Blood Potassium Levels in Chronic Myeloid Leukemia Patient: A Literature Review" has been examined by our external referees and then re-evaluated inhouse.

All referees agree that this manuscript is interesting and potentially acceptable for publication in our journal.

However, a few changes should be made before publication: the reviewers' forms below/comments attached indicate how your manuscript should be modified. To facilitate the review process you should make all changes in your manuscript easily identifiable: you can do this by using a different color.

Should you choose to resubmit, please include a covering letter to explain, point by point, how you have modified your paper in answer to each of the reviewers' comments.

Important: we recommend that you consult the Authors' guidelines of this journal under Submission, as well as its current contents, to ensure that your revised manuscript is written in accordance to the journal editorial standards (in particular, title page, tables and references style).

The revised manuscript, edited in .DOC format, should be resubmitted electronically within 4 weeks from the date of the Editor Decision message.

Although our journal is potentially interested in this paper, please be aware that this is not a statement of acceptance or a promise to accept a revised manuscript. The final decision as to this paper's acceptability for publication will depend on how our current concerns are met.

Thank you very much for sending this interesting work to our journal. We look forward to receiving a revised manuscript.

With best regards,

Dr. Camillo Porta

Chair of Oncology Department of Biomedical Sciences and Human Oncology University of Bari 'A. Moro' Chief, Division of Medical Oncology Policlinico Consorziiale di Bari
editor_oncol@pagepress.site

Editor-in-Chief, Oncology Reviews

ONCOL - Oncology Reviews [paper #547] - Editor Decision - Revisions Required

Reviewer A:

This manuscript reports a review of calcium and potassium unbalances occurring during administration of two TKI inhibitors for CML treatment, nilotinib and imatinib. The strength of the study is the focus on common and overlooked side effects; the weakness is that there are few references to clinical implications of this side effects.

As a general comment, the English language is generally correct.

About the contents: I particularly appreciated the discussion on mechanisms associated with damage to the kidneys. In the Discussion, more insights on the clinical consequences of the described alterations would be useful. The references are well balanced.

Specific comments follow:

1. The Authors should explain why they did not include also dasatinib in their analysis, since dasatinib in many EU countries is an approved first-line treatment for CML;
2. Line 72, concerning dose: it may be useful to mention that the treatment should be continued lifelong
3. Line 87: among the side effects of imatinib, I would include also fluid retention and diarrhea
4. Line 104: better to report QT prolongation in percentage rather than in absolute numbers
5. Line 212: a comment on the possible interaction of TKI with other drugs that affect K levels (e.g., diuretics) could be helpful.

Recommendation: Revisions Required

COVER LETTER

Division of Medical Oncology-Hematology
Department of Internal Medicine
Universitas Lambung Mangkurat/Ulin General Hospital
Banjarmasin, Indonesia

August 21st, 2021

Dear Editor,

We wish to re-submit our manuscript titled “The Effect of Imatinib and Nilotinib on Blood Calcium and Blood Potassium Levels in Chronic Myeloid Leukemia Patient: A Literature Review” for consideration to be published in the Oncology Reviews.

First of all, we would like to thank you, most sincerely for taking your time out and reviewing this manuscript. We especially appreciate the reviewer’s comments about the appreciation for discussion on mechanism associated with damage to the kidneys. We are also extremely grateful for the specific comments for the manuscript because it helped us to identify some items that we might have overlooked.

In the following paragraphs, we provide our responses to the comments/issues stated by the reviewer:

- Comment from Reviewer:** “The Authors should explain why they did not include also dasatinib in their analysis, since dasatinib in many EU countries is an approved first-line treatment for CML”.

Response: In this manuscript, we show the side effects of imatinib and nilotinib on blood potassium and calcium levels, since they are the frontline treatment of CML in Indonesia. Dasatinib was not included in the analysis because it is not available as the frontline treatment of CML patients in Indonesia. Dasatinib was also not included in the manuscript because when it is compared to nilotinib, dasatinib has a quite similar treatment response (CCyR and MMR), but it costs more than nilotinib. In addition, dasatinib has the highest incidence of pulmonary toxicities that might result in permanent drug cessation and cause significant morbidity.
- Comment from Reviewer:** “Line 72, concerning dose: it may be useful to mention that the treatment should be continued lifelong”.

Response: We added the information that most CML patients will continue to take TKI medications for life. The additional information is located at the line 75-76 under the sub-heading “Tyrosine Kinase Inhibitors and Their Side Effects in Patients with Chronic Myeloid Leukemia”.
- Comment from Reviewer:** “Line 87: among the side effects of imatinib, I would include also fluid retention and diarrhea”.

Response: We added these adverse events to the manuscript. The additional information is located at the line 91-92 under the sub-heading “Tyrosine Kinase Inhibitors and Their Side Effects in Patients with Chronic Myeloid Leukemia”.

4. **Comment from Reviewer:** “Line 104: better to report QT prolongation in percentage rather than in absolute numbers”.

Response: We changed the absolute numbers into the percentages. We agree with the reviewer that QT prolongation reports are better represented in percentages when the number of imatinib and nilotinib treated patients are different. The additional information is located at the line 108 under the sub-heading “Tyrosine Kinase Inhibitors and Their Side Effects in Patients with Chronic Myeloid Leukemia”.

5. **Comment from Reviewer:** “Line 212: a comment on the possible interaction of TKI with other drugs that affect K levels (e.g., diuretics) could be helpful”.

Response: We added the example of drugs that potentially would interact with TKIs in terms of potassium level, and the general mechanism of how those drugs might affect the potassium levels. However, to date, increased blood potassium level is only reported as adverse events of TKIs. We could not find any studies that specifically assessed the interaction of TKIs with those drugs and how it might affect the potassium levels in CML patients. Hence, this topic needs further study. The additional information is located at the line 206-211 under the sub-heading “Effects of Tyrosine Kinase Inhibitors on Blood Potassium Level”.

6. **Comment from Reviewer:** “I particularly appreciated the discussion on mechanisms associated with damage to the kidneys. In the Discussion, more insights on the clinical consequences of the described alterations would be useful.”

Response: We have included the clinical consequences of the decrease or increase in potassium level after TKI administration in the paragraph located at the line 198-204. The clinical consequences of the changes in calcium level are shown at the line 281-284.

Following the suggestion from the Editor, we also adjusted the format according to the Guideline for Authors, and included 40 references (instead of 29 in the previous version of the manuscript).

We hope we have addressed all the comments from the Editor and the Reviewer, and revised the manuscript as suggested.

Please address all the correspondence regarding this manuscript to the submitting author, Muhammad Darwin Prenggono, at muh.darwin.prenggono@gmail.com.

Thank you for your consideration of this manuscript.

Sincerely,

Division of Medical Oncology-Hematology
Department of Internal Medicine
Universitas Lambung Mangkurat/Ulin General Hospital
Banjarmasin, Indonesia

ONCOL - Oncology Reviews [paper #547] - Editor Decision – Acceptance

Dear Dr. Muhammad Darwin Prenggono, Alfı Yasmina, Misna Ariyah, Tenri Ashari Wanahari, Nuvita Hasrianti,

We are pleased to inform you that your paper entitled "The Effect of Imatinib and Nilotinib on Blood Calcium and Blood Potassium Levels in Chronic Myeloid Leukemia Patient: A Literature Review" has been accepted for publication.

To make accepted papers immediately available and citable, our journal offers the "ADVANCE ONLINE" publication system. It means that your article will be posted online before print publication in about a week from acceptance and can then be cited with its unique DOI number.

The "ADVANCE ONLINE" can be worked out after receiving:

- 1) the Copyright and License agreement (http://www.pagepressjournals.org/public/License_Agreement.pdf) signed by the corresponding author;
- 2) the Conflict of Interest form (https://www.pagepress.org/public/COI_disclosure.docx) filled in by EACH author;
- 3) the payment of the Article Processing Fee (APC) (<https://www.oncologyreviews.org/site/fee>)

The APC payment can be made by any of the following methods:

PayPal/Credit cards – these are the most recommended and secure payment systems, enabling you to pay without sharing your financial information and getting your payment receipt immediately.
Bank transfer - Bank charges to be borne by payer. Once payment has been processed a regular invoice will be issued.

We advise prompt payment as we are unable to publish accepted articles until payment has been received.

Meanwhile, your paper will undergo copyediting to make it compliant with the Journal's guidelines and explicit for a broad readership. You will have the opportunity of approving or discussing any change made by our Copyeditor by checking the galley proofs. Any final changes in manuscripts will be made at the time of last publication and will be reflected in the final electronic version of the issue.

With kind regards,

Dr. Camillo Porta
Chair of Oncology Department of Biomedical Sciences and Human Oncology University of Bari 'A. Moro' Chief, Division of Medical Oncology Policlinico Consorziiale di Bari
editor_oncol@pagepress.site

Editor-in-Chief, Oncology Reviews

Gambar. Tangkapan layar bukti penerimaan artikel hasil review pakar (*peer-review*) naskah publikasi berjudul "*The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review*" pada sistem pengiriman jurnal oleh Editor-in-Chief Oncology Reviews



Muhammad Darwin Prenggono <muh.darwin.prenggono@gmail.com>

Fwd:

1 message

Paola Granata <paola.granata@pagepress.org>

Wed, Sep 15, 2021 at 5:32 PM

To: Muhammad Darwin Prenggono <muh.darwin.prenggono@gmail.com>

Cc: seribumelati@gmail.com, misnaariyah72@gmail.com, tenri.wanahari@gmail.com, nuvitahasrianti@gmail.com, "Ms. Paola Granata" <paola.granata.pgp@pagepress.org>

Dear Authors

please confirm the receipt of the email below sent on August 27, by the EIC; to start the editing process for your paper we need to receive the article fee and the signed documents:

From: "Dr. Camillo Porta" <editor_oncol@pagepress.site>

To: "Muhammad Darwin Prenggono" <muh.darwin.prenggono@gmail.com>, "Alfi Yasmina" <seribumelati@gmail.com>, "Misna Ariyah" <misnaariyah72@gmail.com>, "Tenri Ashari Wanahari" <tenri.wanahari@gmail.com>, "Nuvita Hasrianti" <nuvitahasrianti@gmail.com>

Subject: ONCOL - Oncology Reviews [paper #547] - Editor Decision - Acceptance

Dear Dr. Muhammad Darwin Prenggono, Alfi Yasmina, Misna Ariyah, Tenri Ashari Wanahari, Nuvita Hasrianti,

We are pleased to inform you that your paper entitled "The Effect of Imatinib and Nilotinib on Blood Calcium and Blood Potassium Levels in Chronic Myeloid Leukemia Patient: A Literature Review" has been accepted for publication.

To make accepted papers immediately available and citable, our journal offers the "ADVANCE ONLINE" publication system. It means that your article will be posted online before print publication in about a week from acceptance and can then be cited with its unique DOI number.

The "ADVANCE ONLINE" can be worked out after receiving:

- 1) the Copyright and License agreement (http://www.pagepressjournals.org/public/License_Agreement.pdf) signed by the corresponding author;
- 2) the Conflict of Interest form (https://www.pagepress.org/public/COI_disclosure.docx) filled in by EACH author;
- 3) the payment of the Article Processing Fee (APC) (<https://www.oncologyreviews.org/site/fee>)

The APC payment can be made by any of the following methods:

PayPal/Credit cards – these are the most recommended and secure payment systems, enabling you to pay without sharing your financial information and getting your payment receipt immediately.

Bank transfer - Bank charges to be borne by payer. Once payment has been processed a regular invoice will be issued.

We advise prompt payment as we are unable to publish accepted articles until payment has been received.

Meanwhile, your paper will undergo copyediting to make it compliant with the Journal's guidelines and explicit for a broad readership. You will have the opportunity of approving or discussing any change made by our Copyeditor by checking the galley proofs. Any final changes in manuscripts will be made at the time of last publication and will be reflected in the final electronic version of the issue.

With kind regards,

Dr. Camillo Porta

Chair of Oncology Department of Biomedical Sciences and Human Oncology University of Bari 'A. Moro' Chief, Division of Medical Oncology Policlinico Consorziale di Bari

editor_oncol@pagepress.site

Editor-in-Chief, Oncology Reviews

[Oncology Reviews](#)

Thank you,
best regards

Dr.ssa Paola Granata

PAGEPress srl

Scientific Publications

via A. Cavagna Sangiuliani 5

27100 Pavia, Italy

T. +39.0382.1549020

F. +39.0382.1727454

www.linkedin.com/company/3264205



The information in this e-mail and in any attachments is confidential and intended solely for the attention and use of the named addressee(s). This information may be subject to legal, professional or other privilege and further distribution of it is strictly prohibited without our permission. If you are not the intended recipient, you are not authorised to and must not disclose, copy, distribute, or retain this message or any part of it, and should notify us immediately. This footnote also confirms that this email has been automatically scanned for the presence of computer viruses, profanities and certain file types.



Muhammad Darwin Prenggono <muh.darwin.prenggono@gmail.com>

ONCOL - Oncology Reviews [paper #547] - Editor Decision - Acceptance

2 messages

Dr. Camillo Porta <editor_oncol@pagepress.site>

Fri, Aug 27, 2021 at 3:53 PM

To: Muhammad Darwin Prenggono <muh.darwin.prenggono@gmail.com>, Alfi Yasmina <seribumelati@gmail.com>, Misna Ariyah <misnaariyah72@gmail.com>, Tenri Ashari Wanahari <tenri.wanahari@gmail.com>, Nuvita Hasrianti <nuvitahasrianti@gmail.com>

Dear Dr. Muhammad Darwin Prenggono, Alfi Yasmina, Misna Ariyah, Tenri Ashari Wanahari, Nuvita Hasrianti,

We are pleased to inform you that your paper entitled "The Effect of Imatinib and Nilotinib on Blood Calcium and Blood Potassium Levels in Chronic Myeloid Leukemia Patient: A Literature Review" has been accepted for publication.

To make accepted papers immediately available and citable, our journal offers the "ADVANCE ONLINE" publication system. It means that your article will be posted online before print publication in about a week from acceptance and can then be cited with its unique DOI number.

The "ADVANCE ONLINE" can be worked out after receiving:

- 1) the Copyright and License agreement (http://www.pagepressjournals.org/public/License_Agreement.pdf) signed by the corresponding author;
- 2) the Conflict of Interest form (https://www.pagepress.org/public/COI_disclosure.docx) filled in by EACH author;
- 3) the payment of the Article Processing Fee (APC) (<https://www.oncologyreviews.org/site/fee>)

The APC payment can be made by any of the following methods:

PayPal/Credit cards – these are the most recommended and secure payment systems, enabling you to pay without sharing your financial information and getting your payment receipt immediately.

Bank transfer - Bank charges to be borne by payer. Once payment has been processed a regular invoice will be issued.

We advise prompt payment as we are unable to publish accepted articles until payment has been received.

Meanwhile, your paper will undergo copyediting to make it compliant with the Journal's guidelines and explicit for a broad readership. You will have the opportunity of approving or discussing any change made by our Copyeditor by checking the galley proofs. Any final changes in manuscripts will be made at the time of last publication and will be reflected in the final electronic version of the issue.

With kind regards,

Dr. Camillo Porta

Chair of Oncology Department of Biomedical Sciences and Human Oncology University of Bari 'A. Moro' Chief, Division of Medical Oncology Policlinico Consorziale di Bari
editor_oncol@pagepress.site

Editor-in-Chief, Oncology Reviews

[Oncology Reviews](#)

Muhammad Darwin Prenggono <muh.darwin.prenggono@gmail.com>

Sat, Sep 25, 2021 at 9:00 PM

To: "Dr. Camillo Porta" <editor_oncol@pagepress.site>, camillo.porta@gmail.com
Bcc: paola.granata@pagepress.org

Dear

Dr. Camillo Porta

Editor-in-Chief of Oncology Reviews

We are glad to hear that our paper entitled "The Effect of Imatinib and Nilotinib on Blood Calcium and Blood Potassium Levels in Chronic Myeloid Leukemia Patients: A Literature Review", Paper # 547, is accepted for publication in Oncology Reviews. Hereby, requested documents such as the copyright and license agreement and the conflict of interest form are attached below.

For the Article Processing Fee (APC) payment, we would like to choose the option of payment from BANK TRANSFER. Can we get the Bank name and Reference Number for our APC invoice payment?

Thank you for your attention.

Kind Regard,

Muhammad Darwin Prenggono, MD, PhD
Division of Medical Oncology
Department of Internal Medicine
Ulin General Hospital
Indonesia

[Quoted text hidden]

6 attachments

-  **COI_disclosure_Ariyah.pdf**
188K
-  **COI_disclosure_Prenggono.pdf**
188K
-  **COI_disclosure_Hasrianti.pdf**
187K
-  **COI_disclosure_Wanahari.pdf**
186K
-  **COI_disclosure_Yasmina.pdf**
187K
-  **License_Agreement.pdf**
326K

Proof Reading Article

1 message

Muhammad Darwin Prenggono <muh.darwin.prenggono@gmail.com>
To: "Dr. Camillo Porta" <editor_oncol@pagepress.site>

Sun, Nov 28, 2021 at 4:47 AM

Dear Editor,

We have carefully read and checked the manuscript, and we suggest the changes below. We also have highlighted the parts to be changed, along with the comments.

List of changes:

1. Page 4, Subtitle "Effect of tyrose kinase inhibitors on blood calcium level": the word "tyrose" in this subtitle should be changed into "tyrosine".
2. Page 4, under the Subtitle "Effect of tyrose kinase inhibitors on blood calcium level", paragraph 1, line1-2: "BCR-ABL" should be in italic, since this is a common style for the name of a gene.
3. Page 7, Table 3, second row, second column: "a" and "nd" should not be separated. It should be written as follows: "and".
4. Page 7, Table 3, second row, second column: we suggest changing "biochemistry serum" into "serum biochemistry".
5. Page 9, Subtitle "Conclusions and discussion": the word "and discussion" should be deleted, so the subtitle change to "Conclusion" only.

Thank you for the formatting and proofreading.

Best regards,

Muhammad Darwin Prenggono, MD, PhD

2 attachments**Letter to Editor (Proofreading).docx**

14K

**547-Article Text-3510-1-10-20211117-AY.pdf**

316K



EMAIL tenri.wanahari@gmail.com

RECIPIENT
3888
Tenri Ashari Wanahari
JL Pramuka Bloc C No. 308
70111 Banjarmasin
Indonesia

SUBJECT
Article Processing Charge(s) - ONCOL REV #547

DESCRIPTION	AMOUNT
OR Article Processing Charge(s) ONCOL REV #547 "The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review" by: Muhammad Darwin Prenggono, Alfi Yasmina, Misna Ariyah, Tenri Ashari Wanahari, Nuvita Hasrianti *Correspondence: muh.darwin.prenggono@gmail.com ; seribumelati@gmail.com ; misnaariyah72@gmail.com ; tenri.wanahari@gmail.com ; nuvitahasrianti@gmail.com	€ 600.00

NOTES THIS INVOICE WAS PAID. THANK YOU.

PAYMENT METHOD
BANK TRANSFER / CONTO BANCARIO
BANCA POPOLARE DI SONDRIO, AG. 1: IT85Y0569611301000005086X83
Intestatario/To be addressed to: **PAGEPRESS SRL**
SWIFT/BIC: **POSOIT22**

DUE DATES
2021-10-05: € 600.00

VAT SUMMARY	TOTAL AMOUNT	TAXES
0% - <i>Escluso art. 7 ter NO UE - DPR 633/72</i>	600.00	€ 0.00

Total amount € 600.00

€ 600.00



Muhammad Darwin Prenggono <muh.darwin.prenggono@gmail.com>

Fwd: ONCOL - Oncology Reviews [paper #547] - Editor Decision - Acceptance

Muhammad Darwin Prenggono <muh.darwin.prenggono@gmail.com>
To: Paola Granata <paola.granata@pagepress.org>

Fri, Oct 1, 2021 at 9:05 PM

Dear Dr. Paola Granata

We have paid the Article Processing Charge (APC) Fee for our article entitled "The Effect of Imatinib and Nilotinib on Blood Calcium and Blood Potassium Levels in Chronic Myeloid Leukemia Patient: A Literature Review" (Paper ID #547) for publication in Oncology Reviews. Please kindly receive the Proof of Payment using Bank Transfer Method, sent by my college and one of the author's article above, Dr. Tenri Ashari Wanahari.

We also would like to update the author's ORCID profile for article meta data. Please kindly add our additional data inside PDF file in the attachment below.

Thank you for your attention.

Regards,
Muhammad Darwin Prenggono, MD, PhD,
Division Medical Oncology and Hematology,
Departement of Internal Medicine,
Faculty of Medicine Universitas Lambung Mangkurat/Ulin General Hospital,
Banjarmasin, Indonesia

[Quoted text hidden]

2 attachments

APC-proof-payment.jpg
1276K



 **ORCID profile.pdf**
79K

ICMJE DISCLOSURE FORM

Date : 14th September, 2021
Your Name : Muhammad Darwin Prenggono
Manuscript Title : The effect of Imatinib and Nilotinib on Blood Calcium and Blood Potassium Levels in Chronic Myeloid Leukemia Patients: A Literature Review
Manuscript number (if known) : 547

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		
		NA	NA
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	NA	NA
3	Royalties or licenses	NA	NA
4	Consulting fees	NA	NA

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	NA	NA
6	Payment for expert testimony	NA	NA
7	Support for attending meetings and/or travel	NA	NA
8	Patents planned, issued or pending	NA	NA
9	Participation on a Data Safety Monitoring Board or Advisory Board	NA	NA
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	NA	NA
11	Stock or stock options	NA	NA
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	NA	NA
13	Other financial or non-financial interests	NA	NA

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Licence to publish

The undersigned

Name author(s) (“the Author(s)”)

grants to

PAGEPress srl (“the Publisher”)

the following licence:

Background

This agreement concerns the publishing of scholarly and/or scientific works, and is intended to reflect a balance between the rights of the Author and the Publisher, according to the following principles:

- The Author and the Publisher believe it is in the general interest to grant maximum access to scholarly and/or scientific works without compromising quality or academic freedom, especially when public resources finance such works;
- The Publisher wishes to receive financial compensation for his contribution in the publication and diffusion of the scholarly work;
- The Author and the Publisher believe that particularly in the so-called subscription model a balance should be achieved between granting maximum access to scholarly and/or scientific works and granting financial compensation for the publication of these works.

Clause 1 Definitions

The following words shall have the following meanings:

1. **Acceptance:** the communication to the Author by the Publisher of his willingness to publish the Author’s work.

PAGEPRESS

pagepress srl
Via Antonio Fogazzaro 5
27058 Voghera (PV), Italy

Office
via A. Cavagna Sangiuliani 5
27100 Pavia, Italy
t. +39.0382.464340
f. +39.0382.34872

VAT IT02125780185

2. **Article:** the published version of the Author's work, entitled:

3. **Publication:** The journal in which the article is published:

Write the name of the journal

PAGEPRESS

pagepress srl
Via Antonio Fogazzaro 5
27058 Voghera (PV), Italy

Office
via A. Cavagna Sangiuliani 5
27100 Pavia, Italy
t. +39.0382.464340
f. +39.0382.34872

VAT IT02125780185

Clause 2 Licence of rights

1. Upon Acceptance, the Author grants to the Publisher a sole licence to exploit the rights listed in clause 2.2 in the Article throughout the world for the full term of the copyright.
2. The sole licence mentioned in clause 2.1 encompasses the right for the Publisher:
 - a. to reproduce the Article in whole or in part, and to communicate the Article to the public in print and/or digital form, whether or not in combination with the works of others, for example the making available to the public via internet or any other network, as part of a database, on-line or off-line, for use by third parties;
 - b. to translate the Article into other languages and to communicate the translation of the Article to the public;
 - c. to create adaptations, summaries or extracts of the Article or other derivative works based on the Article and exercise all of the rights in such adaptations, summaries, extracts and derivative works;

- d. to include the Article, either in translation or as adaptation or summary, in whole or in part in a computerised database and to make this database available to third parties;
 - e. to include the Article, in whole or in part, either in translation or as adaptation or summary, in a reader or compilation;
 - f. to rent or lend the Article to third parties;
 - g. to reproduce the Article by means of reprography, notwithstanding the limitations in the law.
3. The Publisher undertakes that the name of the Author and the source is acknowledged in standard bibliographic citation form.

PAGEPRESS

pagepress srl
Via Antonio Fogazzaro 5
27058 Voghera (PV), Italy

Office
via A. Cavagna Sangiuliani 5
27100 Pavia, Italy
t. +39.0382.464340
f. +39.0382.34872

VAT IT02125780185

Clause 3 Rights reserved by Author

1. The Author retains all other rights with respect to the Article not granted to the Publisher and in particular he can exercise the following rights:

Educational or research use

To reproduce the Article, in whole or in part, and to communicate it or make it available to the public, whether in print and/or digital form, whether as part of a course pack or a compilation, for use in education or research within the Author's own institution or the institutions with which the Author is affiliated.

Dissemination

To upload the Article or to grant to the Author's own institution (or another appropriate organisation) the authorisation to upload the Article, immediately from the date of publication of the journal in which the Article is published (unless that the Author and the Publisher have agreed in writing to a short embargo period, with a maximum of six (6) months):

- a) onto the institution's closed network (e.g., intranet system); and/or
- b) onto publicly accessible institutional and/or centrally organised repositories (such as PubMed Central and other PubMed Central International repositories), provided that a link is inserted to the Article on the Publisher's website.

Preservation

To grant to the Author's own institution (or another appropriate organisation) the authorisation to reproduce the Article for the purpose of preventing it from deteriorating, or if the original is currently in an obsolete format or the technology required to use the original is unavailable, for the purpose of ensuring that the Article continues to be available for education and research purposes;

Future reuse

To reuse whole or part of the Article in a dissertation, compilation or other work.

Personal use

To present the Article at a meeting or conference and to hand out copies of the Article to the delegates attending the meeting.

Use by end users

To grant to end users of the Author's own institution (or another appropriate organisation), the authorisation to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works.

PAGEPRESS

pagepress srl
Via Antonio Fogazzaro 5
27058 Voghera (PV), Italy

Office
via A. Cavagna Sangiuliani 5
27100 Pavia, Italy
t. +39.0382.464340
f. +39.0382.34872

VAT IT02125780185

-
2. For every form of (re)use of the Article as described in the above paragraphs, the Author or the Publisher undertakes always to include the complete source (at least the Author's name, the title and the number of the Publication, and the name of the Publisher), unless this is impossible.

Clause 4 Moral rights

This agreement does not affect the moral rights of the Author in or to the Article. More specifically, the Author asserts his right to be identified as the Author and the right to object to derogatory treatment.

Clause 5 Warranty

1. The Author warrants that he/she is the sole creator of the Article and that the Article does not infringe any existing third-party copyright or moral right.
2. The Author shall hold harmless and indemnify the Publisher from any third party claims resulting from the publication of the Article should there be a breach of this

warranty. The warranties contained in this article also apply to any drawing, photograph or other illustration included in the Article and delivered by the Author.

3. The Author authorises the Publisher to institute, in co-operation with the Author, the necessary steps to prevent third-party infringement of the copyright in the Article. The Author and Publisher undertake to provide each other full co-operation and complete information in this regard. The costs are subject to a separate agreement when the question arises.

Clause 6 Obligation to publish

Subject to the Acceptance, the Publisher undertakes to publish the Article to the customary standard and at the cost and expense of the Publisher within a reasonable period after Acceptance.

Clause 7 Legal relationship

1. The Publisher may transfer the exploitation rights on the Article to a third party, provided that this third party fulfils the Publisher's obligations contained in this agreement towards the Author.
2. If the Author can show that his moral rights are affected by the use of his Article by the Publisher pursuant to a licence, the Author may demand that the Publisher stop said use. The Publisher must honour the request unless this cannot be reasonably asked of him in view of the scientific or historical value of the Article.
3. The Author has the right to terminate this agreement if the Publisher goes into bankruptcy or liquidation or any other arrangement for the benefit of its creditors.
4. Termination of this agreement does not affect any prior valid agreement made by the Publisher with third parties.
5. Nothing in this agreement is intended to confer rights on any third party.

Clause 8 Multiple Authors

In the case of multiple authors, the Author as above identified has the consent of each author to enter this Licence to publish on behalf of them.

PAGEPRESS

pagepress srl
Via Antonio Fogazzaro 5
27058 Voghera (PV), Italy

Office
via A. Cavagna Sangiuliani 5
27100 Pavia, Italy
t. +39.0382.464340
f. +39.0382.34872

VAT IT02125780185

Clause 9 Applicable Law

This agreement shall be governed by and construed in accordance with the country of residence of the Author whose courts shall be courts of competent jurisdiction.

Clause 10 Final clause

The agreement comes into effect immediately on Acceptance and shall remain in force for the lifetime of the copyright in the Article.

PAGEPRESS

pagepress srl
Via Antonio Fogazzaro 5
27058 Voghera (PV), Italy

Office
via A. Cavagna Sangiuliani 5
27100 Pavia, Italy
t. +39.0382.464340
f. +39.0382.34872

VAT IT02125780185

Signed on _____

Date

Signature 39fcc983-4b95-4625-bb51-
e7d20f8af860 Digitally signed by 39fcc983-4b95-4625-
bb51-e7d20f8af860
Date: 2021.09.14 10:39:19 +08'00'

Corresponding Author (on behalf of all co-authors)

Disclaimer for publishing Tables/Figures

In submitting a research article ('article') to any of the journals published by PAGEPress I certify that my paper (including Appendices/Supplementary materials) contains:

n. _____ Tables

and/or

n. _____ Figures

THAT are (*choose one or more options*):

Original: _____ (*specify which tab/fig*)

Modified/reproduced/translated from other sources **not copyrighted** (I already ensured this by contacting the other Publisher/checking the license applied by the other Publisher _____ (*specify which tab/fig*))

Modified/reproduced/translated from other sources **copyrighted**:

permission(s) for reproduction is/are attached _____ (*specify which tab/fig*)

permission(s) for reproduction is/are not required because I checked the license applied by the other Publisher and reproduction is allowed _____ (*specify which tab/fig*)

With the present disclaimer I certify that I am aware of any economical/legal issue and I relieve PAGEPress of all responsibility in publishing the above-mentioned Tables/Figures.

name of the journal

title of the article (or #ID number)

authors

your name

39fcc983-4b95-4625-bb51-
e7d20f8af860

Digitally signed by 39fcc983-4b95-4625-bb51-
e7d20f8af860
Date: 2021.09.14 11:13:11 +0800

your signature

date